NO20012857L - Galantaminsammensetning med kontrollert frigivelse - Google Patents

Galantaminsammensetning med kontrollert frigivelse

Info

Publication number
NO20012857L
NO20012857L NO20012857A NO20012857A NO20012857L NO 20012857 L NO20012857 L NO 20012857L NO 20012857 A NO20012857 A NO 20012857A NO 20012857 A NO20012857 A NO 20012857A NO 20012857 L NO20012857 L NO 20012857L
Authority
NO
Norway
Prior art keywords
controlled release
composition
release galantamine
galantamine composition
controlled
Prior art date
Application number
NO20012857A
Other languages
English (en)
Other versions
NO20012857D0 (no
NO327988B1 (no
Inventor
John Paul Mcgee
Paul Marie Victor Gilis
Valentin Florent Victor Conde
Marc Maurice Germain De Weer
Herman Johannes Catheri Bruijn
Frederick Anne Rodolf Va Dycke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20012857(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20012857L publication Critical patent/NO20012857L/no
Publication of NO20012857D0 publication Critical patent/NO20012857D0/no
Publication of NO327988B1 publication Critical patent/NO327988B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20012857A 1998-12-24 2001-06-08 Galantaminsammensetning med kontrollert frigivelse NO327988B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98204447 1998-12-24
PCT/EP1999/010257 WO2000038686A1 (en) 1998-12-24 1999-12-20 Controlled release galantamine composition

Publications (3)

Publication Number Publication Date
NO20012857L true NO20012857L (no) 2001-06-08
NO20012857D0 NO20012857D0 (no) 2001-06-08
NO327988B1 NO327988B1 (no) 2009-11-02

Family

ID=8234559

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012857A NO327988B1 (no) 1998-12-24 2001-06-08 Galantaminsammensetning med kontrollert frigivelse

Country Status (36)

Country Link
US (3) US7160559B1 (no)
EP (1) EP1140105B1 (no)
JP (1) JP2002533396A (no)
KR (1) KR100437105B1 (no)
CN (1) CN100370990C (no)
AP (1) AP1414A (no)
AR (2) AR022008A1 (no)
AT (1) ATE252386T1 (no)
AU (1) AU775914B2 (no)
BG (1) BG65306B1 (no)
BR (1) BR9916835A (no)
CA (1) CA2358062C (no)
CZ (1) CZ301658B6 (no)
DE (1) DE69912311T2 (no)
DK (1) DK1140105T3 (no)
EA (1) EA004936B1 (no)
EE (1) EE04996B1 (no)
ES (1) ES2211215T3 (no)
HK (1) HK1043062A1 (no)
HR (1) HRP20010463B1 (no)
HU (1) HUP0104778A3 (no)
ID (1) ID29021A (no)
IL (2) IL143899A0 (no)
MY (1) MY122411A (no)
NO (1) NO327988B1 (no)
NZ (1) NZ511643A (no)
OA (1) OA11740A (no)
PL (1) PL349501A1 (no)
PT (1) PT1140105E (no)
SI (1) SI1140105T1 (no)
SK (1) SK287676B6 (no)
TR (1) TR200101822T2 (no)
TW (1) TWI262079B (no)
UA (1) UA79578C2 (no)
WO (1) WO2000038686A1 (no)
ZA (1) ZA200105132B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5558648B2 (ja) 1998-11-23 2014-07-23 デイビス、ボニー アセチルコリンエステラーゼ阻害剤のための投与製剤
CA2358062C (en) 1998-12-24 2006-12-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
NO346973B1 (no) 2002-12-20 2023-03-20 Niconovum Ab Et fysisk og kjemisk stabilt nikotin-inneholdende partikkelformet materiale
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US7250258B2 (en) 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
EP2340813A1 (en) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Solid dosage formulations of galantamine
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
BRPI0608780A2 (pt) * 2005-04-28 2010-11-09 Eisai R&D Man Co Ltd composição contendo fármaco anti-demência
EP1933816A1 (en) * 2005-09-05 2008-06-25 Ranbaxy Laboratories, Ltd. Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament
US20070092568A1 (en) * 2005-10-10 2007-04-26 Gore Subhash P Galantamine compositions
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
AU2007242077B2 (en) * 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
US7955622B2 (en) 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
DE102006056697A1 (de) * 2006-11-30 2008-06-05 Ratiopharm Gmbh Galanthamin-haltiges Arzneimittel mit kontrollierter Freisetzung
PT2120878E (pt) * 2007-02-09 2014-11-05 Alphapharm Pty Ltd Forma farmacêutica contendo duas ou mais substancias ativas em diferentes formas físicas
KR100782310B1 (ko) 2007-03-22 2007-12-06 현대약품 주식회사 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EA201000585A1 (ru) * 2007-10-05 2010-10-29 КРКА, д.д., НОВО МЕСТО Многочастичная матричная система, содержащая галантамин
CA2615137A1 (en) * 2007-12-17 2009-06-17 Pharmascience Inc. Single layered controlled release therapeutic system
EP2116232B1 (de) * 2008-05-09 2012-02-15 Ratiopharm GmbH Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2503996A2 (en) 2009-11-26 2012-10-03 USV Limited Controlled release pharmaceutical compositions of galantamine
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
GR1007767B (el) 2011-07-26 2012-11-19 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου
CA3111941A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
JP2016534063A (ja) 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CN109922800B (zh) 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
EP4327871A3 (en) * 2017-05-19 2024-06-05 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation SODIUM CROMOGLYCATE AND ?-LACTOSE POWDER FORMULATIONS
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
ATE411026T1 (de) 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
CA1326632C (en) * 1988-10-26 1994-02-01 Bonnie Davis Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5519017A (en) 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
AT397345B (de) 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE4301782C1 (de) 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
SK279684B6 (sk) * 1993-06-14 1999-02-11 Janssen Pharmaceutica N.V. Tableta a spôsob jej výroby
DE4319760A1 (de) * 1993-06-15 1994-12-22 Bayer Ag Ipsapiron Arzneimittelzubereitung
EP0711166A1 (en) * 1993-07-22 1996-05-15 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
HU218673B (hu) * 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9514821D0 (en) 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
JP3833314B2 (ja) * 1995-09-08 2006-10-11 武田薬品工業株式会社 発泡性組成物およびその製造方法
JP3693270B2 (ja) * 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
ID22445A (id) * 1996-11-19 1999-10-14 Procter & Gamble Kantongan dan metoda untuk meningkatkan atau membantu ketaatan pasien untuk regimen-regimen obat kompleks
JPH10231242A (ja) 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TW477702B (en) * 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
AU1282099A (en) 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
JP5558648B2 (ja) 1998-11-23 2014-07-23 デイビス、ボニー アセチルコリンエステラーゼ阻害剤のための投与製剤
CA2358062C (en) * 1998-12-24 2006-12-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
US6273260B1 (en) * 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system

Also Published As

Publication number Publication date
HK1043062A1 (en) 2002-09-06
EA200100713A1 (ru) 2001-12-24
EE200100319A (et) 2002-10-15
CN100370990C (zh) 2008-02-27
CA2358062A1 (en) 2000-07-06
KR20010075715A (ko) 2001-08-09
DE69912311T2 (de) 2004-07-29
CA2358062C (en) 2006-12-19
US20060062856A1 (en) 2006-03-23
SK287676B6 (sk) 2011-05-06
DK1140105T3 (da) 2004-02-23
SI1140105T1 (en) 2004-04-30
EA004936B1 (ru) 2004-10-28
EP1140105B1 (en) 2003-10-22
DE69912311D1 (de) 2003-11-27
ATE252386T1 (de) 2003-11-15
US7160559B1 (en) 2007-01-09
NZ511643A (en) 2003-07-25
AU2100600A (en) 2000-07-31
AP2001002219A0 (en) 2001-09-30
IL143899A (en) 2006-04-10
EP1140105A1 (en) 2001-10-10
JP2002533396A (ja) 2002-10-08
IL143899A0 (en) 2002-04-21
ES2211215T3 (es) 2004-07-01
HUP0104778A2 (hu) 2002-04-29
AR022008A1 (es) 2002-09-04
US20060093671A1 (en) 2006-05-04
HRP20010463B1 (en) 2011-02-28
WO2000038686A1 (en) 2000-07-06
AR066313A2 (es) 2009-08-12
BG105564A (en) 2002-01-31
PT1140105E (pt) 2004-03-31
CN1331596A (zh) 2002-01-16
NO20012857D0 (no) 2001-06-08
PL349501A1 (en) 2002-07-29
CZ20012182A3 (cs) 2002-01-16
MY122411A (en) 2006-04-29
HUP0104778A3 (en) 2004-05-28
AU775914B2 (en) 2004-08-19
KR100437105B1 (ko) 2004-06-23
BR9916835A (pt) 2001-09-25
BG65306B1 (bg) 2008-01-31
SK8862001A3 (en) 2002-02-05
UA79578C2 (en) 2007-07-10
NO327988B1 (no) 2009-11-02
CZ301658B6 (cs) 2010-05-19
TR200101822T2 (tr) 2001-11-21
ID29021A (id) 2001-07-26
AP1414A (en) 2005-06-13
HRP20010463A2 (en) 2002-08-31
TWI262079B (en) 2006-09-21
ZA200105132B (en) 2002-06-21
OA11740A (en) 2005-05-13
EE04996B1 (et) 2008-04-15

Similar Documents

Publication Publication Date Title
NO20012857L (no) Galantaminsammensetning med kontrollert frigivelse
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
NO20021540L (no) Sammensetninger med kontrollert frigivelse omfattende nimesulfid
DK0954966T3 (da) Polymere sammensætninger med reguleret frigivelse
NO20004758L (no) Vaksinesammensetning
DK1096937T3 (da) Ranolazinformuleringer med langvarig frigivelse
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
DK0953335T3 (da) Fast deodorantsammensætning
AR027907A1 (es) Composicion de liberacion controlada
ID29430A (id) Komposisi herbisida
ATE254907T1 (de) Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
ATE232364T1 (de) Zuckergusszusammensetzung
DK0880892T5 (da) Midler med reguleret frigivelse
DE69942892D1 (de) Gaserzeugende zusammensetzung
DK1142477T3 (da) Sammensætninger med reguleret frigivelse
DE69928862D1 (de) Zusammensetzung
NO20002126L (no) Formulering med forlenget frigjøring
NO20014301D0 (no) Sammensetninger med kontrollert frigivelse av betahistin
ID26295A (id) Komposisi keras-ultraviolet
ID26485A (id) Komposisi paroksetina
ID28359A (id) Komposisi
DE69939964D1 (de) Gelförmige Zusammensetzung
DE69926614D1 (de) Auskleidungszusammensetzung
ID28785A (id) Komposisi

Legal Events

Date Code Title Description
MK1K Patent expired